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Background. Vancomycin (VAN)-associated acute kidney injury (AKI) is increased when VAN is combined with certain betalactams (BLs) such as piperacillin-tazobactam (TZP) but has not been evaluated with ceftolozane-tazobactam (C/T). Our aim was to
investigate the AKI incidence of VAN in combination with C/T (VAN/C/T) compared with VAN in combination to TZP (VAN-TZP).
Methods. We conducted a multicenter, observational, comparative study across the United States. The primary analysis was a
composite outcome of AKI and risk, injury, failure, loss, end stage renal disease; Acute Kidney Injury Network; or VAN-induced
nephrotoxicity according to the consensus guidelines. Multivariable logistic regression analysis was conducted to adjust for
confounding variables and stratiﬁed Kaplan–Meir analysis to assess the time to nephrotoxicity between the 2 groups.
Results. We included VAN/C/T (n = 90) and VAN-TZP (n = 284) at an enrollment ratio of 3:1. The primary outcome occurred in
12.2% vs 25.0% in the VAN-C/T and VAN-TZP groups, respectively (P = .011). After adjusting for confounding variables, VAN-TZP was
associated with increased odds of AKI compared with VAN-C/T; with an adjusted odds ratio of 3.308 (95% conﬁdence interval, 1.560–
6.993). Results of the stratiﬁed Kaplan–Meir analysis with log-rank time-to-nephrotoxicity analysis indicate that time to AKI was
signiﬁcantly shorter among patients who received VAN-TZP (P = .004). Cox proportional hazards analysis demonstrated that TZP
was consistent with the primary analysis (P = .001).
Conclusions. Collectively, our results suggest that the AKI is not likely to be related to tazobactam but rather to piperacillin, which is a
component in VAN-TZP but not in VAN-C/T.
Keywords. vancomycin; ceftolozane-tazobactam; piperacillin-tazobactam; nephrotoxicity.
Empiric antibiotic therapy with coverage against Pseudomonas
aeruginosa and methicillin-resistant Staphylococcus aureus

Received 02 March 2022; editorial decision 11 August 2022; published online 19 August
2022
Correspondence: M. J. Rybak, Anti-Infective Research Laboratory, Department of Pharmacy
Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State
University, 259 Mack Avenue Detroit, MI 48201 (m.rybak@wayne.edu).
Clinical Infectious Diseases®
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases
Society of America. All rights reserved. For permissions, please e-mail: journals.permissions
@oup.com
https://doi.org/10.1093/cid/ciac670

(MRSA) is recommended in the United States for most
hospital-associated infections [1]. Inappropriate and delayed
empiric therapy is documented to be associated with increased
mortality in P. aeruginosa and MRSA infections, particularly
bacteremia [2–5]. Antipseudomonal beta-lactams (BLs) and
vancomycin (VAN) are considered standard-of-care antibiotics for the empiric coverage of gram-negative and MRSA infections, respectively [6, 7]. VAN has a well-known association
with acute kidney injury (AKI) that varies widely (5%–43%)
due to its dependence on patient-speciﬁc risk factors including
critical illness, VAN exposure, nephrotoxins exposure, and
VAN therapeutic monitoring approach [8–10]. Another
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important risk factor for VAN-induced AKI is the concomitant
use of certain BLs such as piperacillin-tazobactam (TZP) [10–
18]. Evidence demonstrates that the risk of VAN-associated
AKI is increased 3- to 4-fold when VAN is combined with TZP
compared with VAN monotherapy [12, 14–17]. This is concerning because VAN and TZP are a cornerstone in empiric
antibiotic regimens when initiating therapy for patients admitted to the hospital with infections [19]. Cefepime (FEP)
and meropenem (MEM) are alternative antipseudomonal
BLs to TZP that, when used in combination with VAN, result
in signiﬁcantly lower AKI compared with VAN-TZP [12–18,
20, 21]. While the odds of AKI are signiﬁcantly higher with
VAN-TZP compared with VAN-FEP or VAN-MEM, no signiﬁcant difference has been shown to exist between VAN-FEP and
VAN-MEM [12–18, 20, 21].
Ceftolozane-tazobactam (C/T) is an advanced-generation
cephalosporin (ceftolozane) combined in a ﬁxed (2:1) combination with a well-known beta-lactamase inhibitor, tazobactam,
and approved by the US Food and Drug Administration for
complicated urinary tract infections, complicated intraabdominal infections, and nosocomial pneumonia, including hospitalacquired and ventilator-associated bacterial pneumonia [22].
The incidence of AKI with C/T in clinical trials is generally
low (3.8%) in real-world studies, and no studies have evaluated
C/T in combination with VAN [23]. Although C/T contains the
same BL inhibitor as TZP, the AKI impact is thought to be related to the piperacillin component rather than the BL inhibitor
component [24, 25]. Because the incidence of AKI with the
use of C/T in combination with VAN (VAN-C/T) has not yet
been evaluated, our aim was to investigate the risk of nephrotoxicity with VAN-C/T in comparison with VAN in combination
with TZP (VAN-TZP).
METHODS
Study Design and Population

This was a multicenter, retrospective, cohort study conducted
at 18 collaborator sites in 10 geographical locations of the
United States between August 2015 and September 2021.
Patients were eligible if aged ≥18 years, had received
VAN-C/T or VAN-TZP for ≥48 hours, and started no longer
than 24 hours of one another. Patients were excluded for
the following reasons: AKI prior to study drug initiation, baseline serum creatinine (SCr) value >4.0 mg/dL, end stage renal
disease or receipt of chronic or emergent renal replacement
therapy (RRT) prior to study drug initiation, no SCr measurements available, pregnant or nursing, incarcerated, and/or
missing data. For patients who received any combination
more than once during the hospital admission, only the initial
regimen was included. Patients who received subsequent C/T
or TZP courses in combination with VAN were excluded unless
separated by 60 days from the index course.
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Data Collection

Data were extracted retrospectively from the electronic medical
record. Study data were collected and managed using the
Research Electronic Data Capture tool hosted at Wayne State
University [26].

Study Deﬁnitions

The Charlson comorbidity index was used to measure the degree of a patient’s comorbidities. Severity of illness was assessed
using the Acute Physiology and Chronic Health Evaluation II
and Sequential Organ Failure Assessment scores at the onset
of infection, which were deﬁned as the date and time of index
culture collection [27, 28]. Baseline SCr was deﬁned as SCr
measured within 48 hours before to 24 hours after initiation
of the combination. Creatinine clearance (CrCl) and glomerular ﬁltration rate were estimated based on the Cockcroft-Gault
and Chronic Kidney Disease–Epidemiology Collaboration
equations, respectively [29]. The CrCl was calculated relative
to combination initiation time. Appropriate, under-, or over renally adjusted doses of C/T and TZP were deﬁned according to
their package inserts [22, 30]. Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease (RIFLE) criteria
and Acute Kidney Injury Network (AKIN) criteria were used
as deﬁned in the literature [31, 32]. For VAN-induced nephrotoxicity (VIN) according to the consensus guidelines, AKI was
deﬁned as a rise in baseline SCr by ≥50% or ≥0.5 mg/dL,
whichever was greater, sustained over at least 2 consecutive
measurements ranging from the time of antibiotic combination
initiation until 72 hours after combination discontinuation [6].
Concomitant nephrotoxic agents were deﬁned as usage of any
of the following agents systemically for ≥48 hours during the
entire hospital encounter: aminoglycosides, colistin, polymyxin
B, amphotericin B, vasopressors, nonsteroidal antiinﬂammatory drugs, angiotensin-converting enzyme, angiotensin receptor blocker, loop diuretic, tenofovir, or acyclovir. All clinical
outcomes and time to AKI were measured from the combination start time until 72 hours after combination discontinuation. Due to the well-known impact of VAN area under the
curve (AUC) monitoring on clinical outcomes including safety,
it was also evaluated as a potential confounder [6].

Clinical Outcomes and Exposures

The exposure was deﬁned as meeting the study eligibility criteria where patients received VAN-C/T or VAN-TZP for ≥48
hours. The primary outcome was a composite outcome of
AKI as deﬁned by meeting any of the following: RIFLE criteria,
AKIN criteria, or VIN [31–33]. Secondary outcomes included
individual components of the primary outcome, individual
stages of RIFLE and AKIN criteria, AKI requiring RRT, time
to AKI, and length of hospital stay. The patients were followed
for these outcomes during the entire hospital encounter.

Statistical Analyses

When descriptive statistics were used, nominal data were reported as percentages and frequencies and compared using
the χ2 test. Continuous data were reported as medians and
interquartile ranges (IQRs) and compared using the Mann–
Whitney U test. The Kaplan–Meier estimator was used to determine the survival estimate (ie, nonnephrotoxicity) between
patients treated within either study arm where time to event
(ie, nephrotoxicity) analyses. The log-rank test was used to
characterize the event of interest stratiﬁed by exposure (ie,
study arm) and crude rates of AKI (ie, outcome) in the 2 treatment groups. Time to AKI was measured from the time of receipt of the combination until AKI occurrence among patients
who experienced the outcome of interest. Cox proportional
hazards analyses were also examined. To determine the impact
of each combination therapy on AKI risk in both bivariate and
multivariable analyses, multivariable logistic regression analysis was used. To control for residual differences between the
treatment groups in multivariable analysis, all variables with
a P value < .1 in the bivariate matched analysis were included
along with the treatment group in a multivariable model for
AKI. Correlation and causation between variables in the multivariable analysis were evaluated [34]. All tests were 2-sided, and
P values ≤ .05 were considered statistically signiﬁcant. We conducted a secondary subgroup analysis of patients who were
monitored primarily using VAN trough and an analysis of patients who did not receive a concomitant nephrotoxin.
Additionally, the impact of VAN exposure on AKI was assessed
where the VAN steady-state level was introduced as a randomeffect variable in a subgroup of patients with a measured VAN
steady-state level. The mean steady-state VAN trough concentration prior to AKI was introduced to the same logistic regression model used in the primary analysis.
To determine the sample size, we conducted a power analysis
for our hypothesis. Based on previous studies, we anticipated a
conservative estimate of at least a 3-fold increase in AKI among
patients who received VAN-TZP (ie, 29.0%) compared with
VAN combined with another BL (ie, 9.6%) [15]. Therefore, a
sample size of at least 128 patients with 64 in each group was
determined a priori to achieve 80% power at the 95% conﬁdence level. We anticipated that because of convenience sampling, 64 and 192 patients in the VAN-C/T and VAN-TZP
groups, respectively, would be required. All statistical analyses
were performed using SPSS Statistics, IBM SPSS software, version 27.0 (IBM Corp, Armonk, NY) [35].

study prior to commencement. Patient consent was not required for this retrospective analysis.
RESULTS

In total, 450 patients from 16 sites met inclusion criteria and
were screened for study exclusion criteria. After screening,
374 patients were deemed eligible for analyses (VAN-C/T,
n = 90; VAN-TZP, n = 284; Figure 1). Recruitment occurred
from 16 institutions where 12 contributed to both arms and 2
each contributed to TZP and C/T. The majority of VAN-CT
and VAN-TZP came from 2 major academic medical centers
at a rate of 31.1%/13.3% and 17.6%/12.7%, respectively. Of
the patients included in the cohort, the median age was 59.0
years (interquartile range, 45.8–68.3), and most identiﬁed as
male gender (58.3%) and White race (52.9%). Most patients
were admitted from home (70.9%). Common comorbid conditions included diabetes (36.1%) and obesity (31.3%). Common
sources of infection included pneumonia (35.6%) and skin and
soft tissue (24.1%). A comparison of baseline criteria for the patients in each arm is illustrated in Table 1. The composite primary outcome was more common in the VAN-TZP group than
the VAN-C/T group, 25.0% vs 12.2%, respectively (P = .011), in
addition to individual components of the primary outcome
(Table 2). Similarly, each AKIN and RIFLE category was

Ethical Review and Patient Consent

The Wayne State University Human Investigational Review
Board and the Detroit Medical Center Research Review
Committee reviewed and approved the study design and
work before initiation. Additionally, institutional review
boards at each participating site reviewed and approved this

Figure 1. Flowchart of study patients. Some patients may have had more than 1
exclusion criteria upon screening. Abbreviations: AKI, acute kidney injury; CrCl, creatinine clearance; C/T, ceftolozane-tazobactam; RRT, renal replacement therapy;
SCr, serum creatinine; TZP, piperacillin/tazobactam; VAN, vancomycin.
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Table 1. Baseline Demographics and Clinical Characteristics Stratiﬁed by Type of Combination
Characteristic
Age, y
Age >65 y
Sex, male

Ceftolozane-Tazobactam (n = 90)

Piperacillin-Tazobactam (n = 284)

Total Cohort (N = 375)

56.5 [38.8–66.3]

60.0 [47.3–70.8]

59.0 [45.8–68.3]

P Value
.003

24 (26.7)

109 (38.4)

133 (35.6)

.043
.036

61 (67.8)

157 (55.3)

218 (58.3)

0.7 [0.4–0.9]

0.8 [0.7–0.9]

0.8 [0.6–1.0]

.001

Weight

68.1 [54.4–86.4]

79.7 [65.9–95.6]

77.1 [62.1–93.3]

.001

Body mass index, kg/m2

23.2 [18.7–28.7]

26.9 [23.2–33.9]

26.4 [22.1–32.1]

.001

18 (20.0)

99 (34.9)

117 (31.3)

.008

Baseline serum creatinine

Obese
Race
African American

30 (33.3)

90 (31.7)

120 (32.1)

.771

White

51 (56.7)

147 (51.8)

198 (52.9)

.416

Hispanic

2 (2.2)

26 (9.2)

28 (7.5)

.029

Other/unknowna

7 (7.8)

21(7.4)

28 (7.5)

.904

Home

47 (52.2)

218 (76.8)

265 (70.9)

.001

Nursing facility

19 (21.1)

23 (8.1)

42 (11.2)

.001

Admission source

Transfer from outside institution

7 (7.8)

8 (2.8)

15 (4.0)

.037

17 (18.9)

35 (12.3)

52 (13.9)

.117

Medicare

37 (41.1)

124 (43.7)

161 (43.0)

.670

Medicaid

25 (27.2)

61 (21.5)

86 (23.0)

.216

Private

19 (21.1)

60 (21.1)

79 (21.1)

.997

Otherb

9 (10.0)

39 (13.7)

48 (12.8)

.356
.643

Other
Medical insurance

Infection sourcec
Bacteremia, primary

2 (2.2)

9 (3.2)

11 (2.9)

Pneumonia/LRT

54 (60.0)

79 (27.8)

133 (35.6)

.001

Intraabdominal

3 (3.3)

25 (8.8)

28 (7.5)

.086
.425

Infective endocarditis

0 (0)

2 (0.7)

2 (0.5)

Invasive device

2 (2.2)

0 (0)

2 (0.5)

.012

Intravenous catheter

2 (2.2)

0 (0)

2 (0.5)

.012

Bone and joint

11 (12.2)

37 (13.0)

48 (12.8)

.842

Skin and soft tissue

10 (11.1)

80 (28.2)

90 (24.1)

.001

Urinary

14 (15.6)

19 (6.7)

33 (8.8)

.010

3 (3.3)

8 (2.8)

11 (2.9)

.801

0 (0)

21 (7.4)

21 (5.6)

.008

Other
Unknown
Comorbid conditions
Any immunosuppression factor

13 (14.4)

28 (9.9)

41 (11.0)

.225

AIDS

1 (1.1)

2 (0.7)

3 (0.8)

.706

Cystic ﬁbrosis

6 (6.7)

0 (0)

6 (1.6)

.001

Cytotoxic chemotherapy in preceding 90 d

4 (4.4)

16 (5.6)

20 (5.3)

.662

High-dose corticosteroids

2 (2.2)

4 (1.4)

6 (1.6)

.592

0 (0)

2 (0.7)

2 (0.5)

.425

2 (2.2)

3 (1.1)

5 (1.3)

.401

31 (34.4)

61 (21.5)

92 (24.6)

.013
.688

Human immunodeﬁciency virus without AIDS
Neutropenia
Chronic obstructive pulmonary disease
Connective tissue diseased
Cerebrovascular diseasee
Dementia
Diabetes, any

4 (4.4)

10 (3.5)

14 (3.7)

10 (11.1)

20 (7.0)

30 (8.0)

.216

3 (3.3)

16 (5.6)

19 (5.1)

.386

38 (42.2)

97 (34.2)

135 (36.1)

.165

11 (12.2)

25 (8.8)

36 (9.6)

.338

Heart failure

9 (10.0)

32 (11.3)

41 (11.0)

.737

Liver disease, any

6 (6.7)

18 (6.3)

24 (6.4)

.912

With end organ damage

Moderate/severef

1 (1.1)

9 (3.2)

10 (2.7)

.292

Mechanically ventilated within 24 h of study drug

42 (46.7)

50 (17.6)

92 (24.6)

.001

Mental healthg

16 (17.8)

36 (12.7)

52 (13.9)

.223

3 (3.3)

6 (2.1)

9 (2.4)

.510

Myocardial infarction

7 (7.8)

17 (6.0)

24 (6.4)

.546

Neurological disease

13 (14.4)

20 (7.0)

33 (8.8)

.031

None

12 (13.3)

65 (22.9)

77 (20.6)

.051

Peripheral vascular diseaseh

8 (8.9)

32 (11.3)

40 (10.7)

.525

Peptic ulcer disease

3 (3.3)

4 (1.4)

7 (1.9)

.240

Moderate to severe chronic kidney disease
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Table 1. Continued
Ceftolozane-Tazobactam (n = 90)

Piperacillin-Tazobactam (n = 284)

Total Cohort (N = 375)

Tumor with metastasis

2 (2.2)

28 (9.9)

30 (8.0)

.020

Tumor without metastasis

7 (7.8)

14 (4.9)

21 (5.6)

.306
.002

Characteristic

P Value

Severity of illness factors
ICU within 24 h of study drug

47 (52.2)

95 (33.5)

142 (38.1)

12.0 [5.0–25.0]

6.0 [3.0–11.3]

7.0 [4.0–14.0]

.001

2.0 [2.0–4.0]

2.0 [1.0–3.0]

2.0 [2.0–3.0]

.005

83 (92.2)

186 (65.5)

269 (71.9)

.001

Receipt of potential nephrotoxin for ≥48 h

36 (40.0)

97 (34.2)

133 (35.6)

.313

Angiotensin-converting enzyme inhibitors

3 (3.3)

25 (8.8)

28 (7.5)

.086

ICU length of stay, di
Charlson comorbidity index score
Infectious diseases consult
Factors associated with acute kidney injury

Acyclovir

2 (2.2)

3 (1.1)

5 (1.3)

.401

Angiotensin II receptor blocker

2 (2.2)

11 (3.9)

13 (3.5)

.456

11 (12.2)

2 (0.7)

13 (3.5)

.001

2 (2.2)

0 (0)

2 (0.5)

.012

Diuretic, loop

13 (14.4)

37 (13.0)

50 (13.4)

.731

Intravenous contrast

28 (31.1)

104 (36.6)

132 (35.3)

.341

Aminoglycosides
Colistin/polymyxin B

Nonsteroidal antiinﬂammatory drugs
Vasopressor within 24 h of study drug

3 (3.3)

22 (7.7)

25 (6.7)

.144

17 (18.9)

31 (10.9)

48 (12.8)

.049

5.1 [3.1–9.1]

4.8 [3.2–7.5]

4.9 [3.2–7.8]

.461

27 (29.7)

76 (26.8)

103 (27.5)

.588

1000 [750–1250]

1250 [1000–1312]

1250 [1000–1250]

.043

VAN
Duration, d
Loading dose (>20 mg/kg actual body weight)
Maintenance dose, mg
Dosing interval
Q8 h

21 (23.1)

55 (19.4)

76 (20.3)

.443

Q12 h

48 (52.7)

160 (56.3)

208 (55.5)

.549

Q18 h

0 (0)

5 (1.8)

5 (1.3)

.203

Q24 h

22 (24.2)

64 (22.5)

86 (22.9)

.746

9.0 [6.0–15.0]

9.0 [7.0–15.0]

9.0 [6.3–15.0]

.552

80 (88.9)

265 (93.3)

345 (92.2)

.172

16.2 [10.1–21.1]

14.3 [10.0–17.9]

14.7 [10.0–18.6]

.023

52 (65.0)

162 (61.4)

214 (62.2)

.557

Second steady-state trough (mg/L)

17.0 [13.5–22.9]

16.7 [12.9–20.2]

16.8 [13.1–20.5]

.561

Third steady-state VAN was measured

27 (51.9)

69 (43.3)

96 (45.5)

.284

Total number of doses
Steady-state VAN was measured
Steady-state trough (mg/L)
Second steady-state VAN was measured

19.3 [13.2–22.9]

17.1 [13.3–22.7]

18.4 [13.3–22.8]

.663

VAN AUC calculated

Third steady-state trough (mg/L)

14 (15.6)

56 (19.7)

70 (18.7)

.378

AUC (mg × h/L)

537.6 [405.4–619.0]

455.5 [376.0–546.8]

463.2 [376.0–552.5]

.223

2 (14.3)

7 (12.5)

9 (12.9)

.858

Second AUC calculated
AUC (mg × h/L)

501.5 [420.0–501.5]

530.0 [426.0–744.0]

530.0 [423.0–679.0]

.558

Third AUC calculated

0 (0)

1 (14.3)

1 (11.1)

.571

AUC (mg × h/L)

NA

590.0

590.0

NA

Beta-lactam
Duration, d

6.0 [3.3–10.1]

5.0 [3.4–7.6]

5.0 [3.4–8.0]

.364

Dose, mg

750 mg: 3 (3.3)

4.5 g: 155 (54.6)

NA

NA

1.5 g: 27 (30.0)

3.375 g: 129 (45.4)

NA

NA

Q8 h: 90 (100)

Q6 h: 110 (38.7)

NA

NA

NA

Q8 h: 173 (60.9)

NA

NA

NA

Q12 h: 1 (0.4)

NA

NA

NA

214 (75.4)

NA

NA

3 g: 60 (66.7)
Dosing interval

Extended infusion

Data demonstrated as median [interquartile range] or number (percentage).
Abbreviations: AUC, area under the curve; ICU, intensive care unit; LRT, lower respiratory tract; NA, non-applicable; VAN, vancomycin.
a

Other (n = 12), declined (n = 6).

b
c

Unavailable (n = 18), mixed (n = 8), uninsured/self-pay (n = 6).

Patient can have more than 1 source.

d

Osteoarthritis or rhematic arthritis.

e

Stroke or transient ischemic attack.

f

Portal hypertension or cirrhosis.

g

Substance abuse (n = 23), depression (n = 10), schizophrenia (n = 6), anxiety (n = 4), bipolar disorder (n = 3).

h

Deep venous thrombosis or chronic venous disease immunodeﬁciency syndrome.

i

ICU days within patients who got admitted in the ICU (n =142).
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Table 2. Primary and Secondary Clinical Outcomes Between Patients by Type of Combination
Ceftolozane-Tazobactam
(n = 90)

Piperacillin-Tazobactam
(n = 284)

3 (27.3)

29 (40.8)

32 (8.6)

.391

0 (0)

14 (4.9)

14 (3.7)

NA

Daptomycin

0 (0)

5 (17.2)

5 (1.8)

NA

Linezolid

0 (0)

4 (13.8)

4 (1.4)

NA

Trimethoprim/sulfamethoxazole

0 (0)

2 (6.9)

2 (0.7)

NA

AMP/SUL

0 (0)

1 (3.4)

1 (0.4)

NA

Clindamycin

0 (0)

1 (3.4)

1 (0.4)

NA

Cephalexin

0 (0)

1 (3.4)

1 (0.4)

NA

BL was discontinued

0 (0)

20 (7.0)

20 (5.4)

NA

BL was switched

0 (0)

12 (4.2)

12 (3.2)

NA

Cefepime

0 (0)

4 (1.4)

4 (1.1)

NA

AMP/SUL

0 (0)

2 (0.7)

2 (0.5)

NA

Ceftriaxone

0 (0)

2 (0.7)

2 (0.5)

NA

Levoﬂoxacin

0 (0)

2 (0.7)

2 (0.5)

NA

Ciproﬂoxacin

0 (0)

1 (0.4)

1 (0.3)

NA

Ertapenem

0 (0)

1 (0.4)

1 (0.3)

NA

AKI, primarya

11 (12.2)

71 (25.0)

82 (21.9)

.011

Risk, Injury, Failure, Loss, End Stage Renal Disease, any

11 (12.2)

53 (18.7)

64 (17.1)

.157

Risk

7 (7.7)

20 (7.0)

27 (7.2)

NA

Injury

1 (3.3)

15 (5.3)

16 (4.3)

NA

Failure

3 (3.3)

18 (6.3)

21 (5.6)

NA

11 (12.2)

70 (24.6)

81 (21.7)

.013

Stage 1

7 (7.7)

38 (13.4)

45 (12.0)

NA

Stage 2

1 (1.1)

16 (5.6)

17 (4.5)

NA

Stage 3

3 (3.3)

16 (5.6)

19 (5.1)

NA

VAN-induced nephrotoxicity

10 (11.1)

51 (18.0)

61 (16.3)

.126

Nephrology consult

5 (45.5)

17 (23.9)

22 (26.8)

.134

Characteristic

Total Cohort
(n = 374)

P Value

Discontinuation
VAN was discontinued
VAN was switched

Nephrotoxicity

Acute Kidney Injury Network, any

Renal replacement therapy
Time to AKI, hb

3 (3.3)

5 (1.8)

8 (2.1)

.369

119.4 [61.7–250.3]

106.3 [60.4–262.4]

93.2 [54.0–191.1]

.314

Peak SCr during AKI

1.6 [1.4–2.1]

1.5 [1.2–2.0]

1.5 [1.2–2.0]

.659

Time to resolution, dc

3.6 [1.6–3.6]

6.0 [2.0–9.1]

5.6 [2.0–8.8]

.259

SCr at discharge

1.4 [0.8–2.1]

1.1 [0.7–1.5]

1.1 [0.8–1.6]

.259

Data demonstrated as median [interquartile range] or number (percentage).
Abbreviations: AMP/SUL, ampicillin/sulbactam; AKI, acute kidney injury; BL, beta-lactam; NA, non-applicable; SCr, serum creatinine; VAN, vancomycin.
a

The primary outcome was a composite outcome of AKI deﬁned as Risk, Injury, Failure, Loss, End Stage Renal Disease criteria, Acute Kidney Injury Network criteria, or VAN consensus
guideline deﬁnition. Even among subgroups of institutions with the highest recruitment of cases, AKI was lower with ceftolozane-tazobactam (C/T) compared with
piperacillin-tazobactam (TZP) and consistent with the primary analysis (C/T at 14.3%) vs (TZP at 30.0%).

b

Measured from combination therapy date.

c

Deﬁned as at least 50% resolution in initial serum creatinine abnormality measured from AKI day.

more common in the VAN-TZP group compared with the
VAN-C/T group. VAN was discontinued in 39% of patients
who experienced AKI (n = 82), and discontinuation was higher
for VAN-TZP (40.8%) vs VAN-C/T (27.8%); however, this was
not statistically signiﬁcant (P = .391). In the univariate analysis,
notable signiﬁcant risk factors for AKI included obesity, liver
disease, intensive care unit (ICU) length of stay, receipt of vasopressors, VAN dose, and VAN duration (Table 3).
Multivariable analyses of risk factors for AKI demonstrated
that the type of antipseudomonal BL was signiﬁcantly associated with AKI (Table 4). After adjusting for confounding variables, receipt of VAN-TZP was associated with increased
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odds of AKI compared with receipt of VAN-C/T, with an adjusted odds ratio (aOR) of 3.308 (95% conﬁdence interval
[CI], 1.560–6.993). Additionally, results of the stratiﬁed
Kaplan–Meier with log-rank time-to-nephrotoxicity analysis
indicated that time to AKI was signiﬁcantly shorter among patients who received VAN-TZP than those who received
VAN-C/T (P = .004; Figure 2). When a Cox proportional hazards model for time to AKI was conducted, it was consistent
with the primary analysis. TZP was independently associated
with an increased incidence of AKI with a hazard ratio of 3.2
(95% CI, 1.632–6.331; P < .001). When a subanalysis of patients
with a recorded steady-state VAN trough (n = 345) was

conducted and the steady-state VAN trough was inserted as a
random-effect variable, the results were consistent with the primary analysis and, again, statistically signiﬁcant where
VAN-TZP combinations were associated with an aOR of
4.210 (95% CI, 1.236–14.492; Supplementary Table 1). The subanalysis that excluded patients who received any nephrotoxic
agent within 48 hours of initiation (n = 241) demonstrated similar results where the aOR was 2.590 (95% CI, 1.051–6.410;
Supplementary Table 2).
DISCUSSION

Receipt of empiric antibiotic therapy that consisted of VAN plus
an antipseudomonal BL is common for patients with suspected
healthcare-associated infections. In this large, multicenter, cohort
study, we present the ﬁrst report of nephrotoxicity outcomes with
VAN-C/T combination therapy. We detected signiﬁcantly higher
odds (>3-fold) of AKI in patients who received VAN-TZP compared with VAN-C/T, even after controlling for independent predictors of AKI. VAN exposure and related characteristics were
well balanced between groups. Notably, patients who received
VAN-C/T were more likely to be critically ill, admitted from nursing homes, and have an infectious diseases consult compared with
patients who received VAN-TZP. Collectively, these factors are to
be expected due to C/T enhanced in vitro activity against
multidrug-resistant pathogens, which are frequently seen in critically ill patients and those admitted from nursing homes, making
it a potentially favorable option compared with TZP.
AKI incidence in the VAN-TZP group was 25%, which is consistent with prior literature (ie, 11%–48%) [10–13, 15, 18, 21].
AKI incidence in the VAN-C/T group was 12.2%, which is higher
than AKI in C/T patients (3.8%) in the real-world setting and
could be comparable to the odds of AKI with VAN alone
[8, 9, 23]. On the other hand, AKI incidence in the VAN-C/T
group was 12.2%, which is similar to previously described rates
for VAN-FEP and VAN-MEM combinations [10–13, 17, 21].
After adjusting for potential confounders, odds of AKI with
VAN-TZP vs VAN-C/T were fairly similar to those reported
when VAN-TZP was compared with other VAN-BL combinations or VAN monotherapy (aOR = 3.3) [12, 15]. This suggests
that the addition of C/T to VAN, when clinically warranted,
may not add an accumulative AKI risk than what is perceived
with VAN monotherapy.
It is important to note that our ﬁndings were primarily driven by AKI graded as stage 1 using AKIN criteria, which is consistent with the VAN AKI and VAN-BL combination literature
[9, 10, 16, 17]. Because elevated VAN trough values are VAN
exposure variables that are highly associated with nephrotoxicity, we conducted a secondary analysis in a subgroup of
patients with VAN monitored via trough rather than AUC
[6, 36, 37]. When using VAN trough as a random-effect variable, the results were consistent with the primary analysis

that demonstrated that AKI with VAN-TZP occurred more frequently than with VAN-C/T. In fact, the secondary analysis
demonstrated a relatively higher odds than the primary analysis
(ie, aOR of 4.2 vs 3.3), suggesting that the method of VAN
monitoring impacts AKI incidence when VAN-BL combinations are used. This is consistent with a previous report demonstrating slightly higher AKI incidence in VAN-TZP patients
monitored using trough vs those monitored using AUC,
17.8% and 13.6% respectively (P = .371) [38]. Further research
is warranted to investigate the factors independently associated
with AKI in VAN-TZP patients monitored using AUC. The
median time to AKI in the entire cohort was 3.8 days. Few studies have assessed the time to AKI incidence in VAN combinations, and the majority did not detect a statistically signiﬁcant
difference between that of VAN-TZP and comparators [12].
Similarly, we found no signiﬁcant difference in time to AKI between VAN-C/T and VAN-TZP. Time to AKI in historical
VAN-TZP studies was longer, with an average of 8 days, which
may have been the result of those studies excluding patients
with AKI occurring within 48–72 hours of combination therapy and heterogeneity among antibiotic durations [12]. It was
expected that the need for RRT is more common for
VAN-C/T than VAN-TZP due to the higher proportion of
ICU patients in the VAN-C/T group. This is also consistent
with ﬁndings comparing VAN-TZP to other BL combinations
in critically ill patients [11]. Last, the results of the stratiﬁed
Kaplan–Meier analysis identiﬁed signiﬁcant differences in
time to AKI for VAN-TZP compared with VAN-C/T (P = .004),
which is consistent with the primary analysis.
The added nephrotoxicity of certain BLs when combined with
VAN may be driven by oxidative stress on the proximal tubule
already placed by VAN via intracellular BL accumulation, which
varies among BLs according afﬁnity to organic anion
transporter-3 (OAT-3) [25, 39]. VAN poses mitochondrial
stress, inducing cardiolipin peroxidation of mitochondria in
the proximal tubular cells, resulting in apoptosis via reactive oxygen species [40]. The presence of VAN accentuates differences
in the proclivity among BLs to induce proximal tubular injury.
The CAMERA-2 trial unequivocally demonstrated the greater
nephrotoxic potential of antistaphylococcal BLs compared with
cefazolin when combined with VAN in a prospective, blinded,
randomized trial of MRSA bacteremia [41]. Wolman et al characterized differences in afﬁnity of various BLs to be taken up by
OAT-3–expressing cells and inhibit OAT-3 based on hydrophobicity [39]. They found that log10P (octanol: water partition coefﬁcient) between BLs with afﬁnity to OAT-3 was +1.41
compared with –1.54 to BLs without afﬁnity. Examination of
the inhibitory activity of OAT-3 by BL shows a very close relationship to BL that is more or less likely to result in nephrotoxicity when combined with VAN, with those with less inhibition
(ie, less binding) being less nephrotoxic. Using this analysis, we
can predict that ceftolozane (log10P = –.21) would have much
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Table 3. Risk Factors for Acute Kidney Injury With Univariate Analysis
AKI (n = 82)

No AKI (n = 292)

Total Cohort (n = 374)

59.5 [45.0–68.0]

59.0 [46.0–70.0]

59.0 [45.8–68.3]

.711

Age >65 y

29 (35.4)

104 (35.6)

133 (35.6)

.967

Sex, male

45 (54.9)

173 (59.2)

218 (58.3)

.478

0.8 [0.6–0.9]

0.7 [0.6–0.9]

0.8 [0.6–1.0]

.969

Weight

81.0 [67.7–95.1]

67.0 [61.0–93.1]

77.1 [62.1–93.3]

.157

Body mass index, kg/m2

27.5 [23.9–34.4]

26.0 [21.5–31.8]

26.4 [22.1–32.1]

.031

33 (40.2)

84 (28.8)

117 (31.3)

.048

Characteristic
Age, y

Baseline serum creatinine

Obese

P Value

Race
African American

26 (31.7)

94 (32.2)

120 (32.1)

.934

White

38 (46.3)

160 (54.8)

198 (52.9)

.175

Hispanic

7 (8.5)

21 (7.2)

28 (7.5)

.683

71 (86.6)

275 (94.2)

346 (92.5)

.021

Home

51 (62.2)

214 (73.3)

265 (70.9)

.051

Nursing facility

10 (12.2)

32 (11.0)

42 (11.2)

.754

1 (1.2)

14 (4.8)

15 (4.0)

.145

20 (24.4)

32 (11.0)

52 (13.9)

.002

Medicare

32 (39.0)

129 (44.2)

161 (43.0)

.405

Medicaid

23 (28.0)

63 (21.6)

86 (23.0)

.218

Private

17 (20.7)

62 (21.2)

79 (21.2)

.922

Otherb

20 (24.4)

32 (11.0)

52 (13.9)

.002
.296

Other/unknowna
Admission source

Transfer from outside institution
Other
Medical insurance

Infection sourcec
Bacteremia, primary

1 (1.2)

10 (3.4)

11 (2.9)

Pneumonia/LRT

31 (37.8)

102 (34.9)

133 (35.6)

.631

Intraabdominal

8 (9.8)

20 (6.8)

28 (7.5)

.377

Infective endocarditis

0 (0)

2 (0.7)

2 (0.5)

.452

Invasive device

0 (0)

2 (0.7)

2 (0.5)

.452

Intravenous catheter

0 (0)

2 (0.7)

2 (0.5)

.452

Bone and joint

12 (14.6)

36 (12.3)

48 (12.8)

.581

Skin and soft tissue

19 (23.2)

71 (24.3)

90 (24.1)

.830

Urinary

6 (7.3)

27 (9.2)

33 (8.8)

.586

Other

3 (3.7)

8 (2.7)

11 (2.9)

.663

Unknown

3 (3.7)

18 (6.2)

21 (5.6)

.384

Comorbid conditions
Any immunosuppression factor

10 (12.2)

31 (10.6)

41 (11.0)

.686

AIDS

1 (1.2)

2 (0.7)

3 (0.8)

.632

Cystic ﬁbrosis

1 (1.2)

5 (1.7)

6 (1.6)

.754

Cytotoxic chemotherapy in preceding 90 d

5 (6.1)

15 (5.1)

20 (5.3)

.733

High-dose corticosteroids

2 (2.4)

4 (1.4)

6 (1.6)

.496

Human immunodeﬁciency virus without AIDS

1 (1.2)

1 (0.3)

2 (0.5)

.336

Neutropenia
Chronic obstructive pulmonary disease

21 (25.6)

71 (24.3)

92 (24.6)

.810

Connective tissue diseased

2 (2.4)

12 (4.1)

14 (3.7)

.481

Cerebrovascular diseasee

7 (8.5)

23 (7.9)

30 (8.0)

.846

Dementia

7 (8.5)

12 (4.1)

19 (5.1)

.107

33 (40.2)

102 (34.9)

135 (36.1)

.376

11 (13.4)

25 (8.6)

36 (9.6)

.188

9 (11.0)

32 (11.0)

41 (11.0)

.997

8 (9.8)

16 (5.5)

24 (6.4)

.163

3 (3.7)

7 (2.4)

10 (2.7)

.532

Diabetes, any
With end organ damage
Heart failure
Liver disease, any
Moderate/severef
Mechanically ventilated within 24 h of study drug

22 (26.8)

70 (24.0)

92 (24.6)

.596

Mental healthg

10 (12.2)

42 (14.4)

52 (13.9)

.613

Moderate to severe chronic kidney disease

3 (3.7)

6 (2.1)

9 (2.4)

.402

Myocardial infarction

3 (3.7)

21 (7.2)

24 (6.4)

.249

Neurological disease

7 (8.5)

26 (8.9)

33 (8.8)

.917
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Table 3. Continued
AKI (n = 82)

No AKI (n = 292)

Total Cohort (n = 374)

17 (20.7)

60 (20.5)

77 (20.6)

.971

Peripheral vascular diseaseh

6 (7.3)

34 (11.6)

40 (10.7)

.263

Peptic ulcer disease

2 (2.4)

5 (1.7)

7 (1.9)

.668

Tumor with metastasis

7 (8.5)

23 (7.9)

30 (8.0)

.846

Tumor without metastasis

5 (6.1)

15 (5.5)

21 (5.6)

.830

Characteristic
None

P Value

Severity of illness factors
ICU within 24 h of study drug
ICU length of stay, di
Charlson comorbidity index score

38 (46.3)

104 (35.7)

142 (38.1)

.081

10.0 [5.0–16.3]

7.0 [3.0–12.0]

7.0 [4.0–14.0]

.046

2.0 [2.0–3.0]

2.0 [1.0–3.0]

2.0 [2.0–3.0]

.363

Health exposure
Recent antibiotic exposure ≥24 h within 90 d

28 (34.1)

102 (34.9)

130 (34.8)

.895

Recent hospital admission ≥48 h within 90 d

27 (32.9)

122 (41.8)

149 (39.8)

.148

Recent surgery within 30 d
Infectious diseases consult

6 (7.3)

34 (11.6)

40 (10.7)

.263

54 (65.9)

215 (73.6)

269 (71.9)

.166

Factors associated with AKI
Receipt of a potential nephrotoxin for at least 48 h

29 (35.4)

104 (35.6)

133 (35.6)

.967

Angiotensin-converting enzyme inhibitors

5 (6.1)

23 (7.9)

28 (7.5)

.589

Acyclovir

1 (1.2)

4 (1.4)

5 (1.3)

.917

Angiotensin II receptor blocker

1 (1.2)

12 (4.1)

13 (3.5)

.207

Aminoglycosides

1 (1.2)

12 (4.1)

13 (3.5)

.207

Colistin/polymyxin B

1 (1.2)

1 (0.3)

2 (0.5)

.336

Diuretic, loop

12 (14.6)

38 (13.0)

50 (13.4)

.703

Intravenous contrast

34 (41.5)

98 (33.6)

132 (35.3)

.186

Nonsteroidal antiinﬂammatory drugs

5 (6.1)

20 (6.8)

25 (6.7)

.810

Vasopressor

9 (11.0)

12 (4.1)

21 (5.6)

.017

10.0 [6.5–17.0]

9.0 [6.0–15.0]

4.9 [3.2–7.8]

.035

22 (26.8)

81 (27.7)

103 (27.5)

.870

1250 [1000–1500]

1250 [1000–1250]

1250 [1000–1250]

.050

Vancomycin
Duration, d
Loading dose (>20 mg/kg actual body weight)
Maintenance dose, mg
Dosing interval
Q8 h

13 (15.9)

63 (21.6)

76 (20.3)

.255

Q12 h

46 (56.1)

162 (55.5)

208 (55.6)

.921
.917

Q18 h

1 (1.2)

4 (1.4)

5 (1.3)

Q24 h

22 (26.8)

63 (21.6)

85 (22.7)

.316

10.0 [6.5–17.0]

9.0 [6.0–15.0]

9.0 [6.3–15.0]

.316

Total number of doses
Steady-state VAN measured
First steady-state trough (mg/L)
Second steady-state VAN was measured
Second steady-state trough (mg/L)
Third steady-state VAN was measured
Third steady-state trough (mg/L)
VAN AUC calculated
VAN AUC (mg × h/L)

75 (91.5)

270 (92.5)

345 (92.2)

.764

15.4 [11.0–19.6]

14.2 [9.7–18.4]

14.7 [10.0–18.6]

.127

52 (96.3)

162 (60.2)

214 (62.2)

.150

17.4 [15.2–23.8]

16.5 [12.2–19.9]

16.8 [13.1–20.5]

.006

29 (55.8)

67 (42.1)

96 (45.5)

.087

20.3 [14.0–26.4]

16.9 [13.0–20.5]

18.4 [13.3–22.3]

.018

12 (14.6)

58 (19.9)

70 (18.7)

.286

488.0 [421.0–547.0]

455.5 [376.0–553.5]

463.2 [376.0–552.5]

.821

Second AUC calculated

1 (8.3)

8 (13.8)

9 (12.9)

.607

VAN AUC (mg × h/L)

583.0

501.0 [421.5–711.5]

530.0 [423.0–679.0]

.699

0 (0)

1 (12.5)

1 (11.1)

0 (0)

590

590

Third AUC calculated
VAN AUC (mg × h/L)

.708
NA

Data demonstrated as median [interquartile range] or number (percentage).
Abbreviations: AKI, acute kidney injury; AUC, area under the curve; ICU, intensive care unit; LRT, lower respiratory tract; NA, non-applicable; VAN, vancomycin.
a

Other (n = 12), declined (n = 6).
Unavailable (n = 18), mixed (n = 8), uninsured/self-pay (n = 6).

b
c

Patient can have more than 1 source.

d

Osteoarthritis or rhematic arthritis.

e

Stroke or transient ischemic attack.

f

Portal hypertension or cirrhosis.
Substance abuse (n = 23), depression (n = 10), schizophrenia (n = 6), anxiety (n = 4), bipolar disorder (n =3).

g
h

Deep venous thrombosis or chronic venous disease immunodeﬁciency syndrome.

i

ICU days within patients who got admitted in the ICU (n = 142).

Vancomycin Beta-lactams Nephrotoxicity • CID • 9

Table 4.
374)

Multivariable Analyses of Acute Kidney Injury Risk Factors (n =

Odds Ratio (95% CI)

Variable

Univariate Analysis
[95% CI]

Multivariable Logistic
Regression [95% CI]

Admission, homea

0.506 [.287–.895]

0.481 [.275–.843]

Body mass index

1.007 [.981–1.034]

…

Piperacillin-tazobactam

3.333 [.042–1.547]

3.308 [6.993–1.560]
…

Medical insurance, other

0.897 [.406–1.983]

Race, otherb

0.306 [.130–.722]

Intensive care unit within
24 h of study drug

1.393 [.770–2.519]

…
2.317 [1.152–4.661]

0.323 [.139–.751]

Recipient of vasopressors

1.927 [.892–4.161]

Vancomycin, d

1.001 [.990–1.013]

…

Vancomycin,
maintenance dose, g

1.690 [.732–3.901]

1.908 [.891–4.083]

Data demonstrated as median [interquartile range].
Abbreviation: CI, conﬁdence interval.
No variable was introduced as a random-effect variable; goodness of ﬁt was P = .312. The
variables are indicated between [] were not introduced into the multivariate analysis due
to a correlation or causation with other variables in the model and the variable of lowest P
value in the bivariate analyses was selected (intensive care unit [ICU] within 24 hours of
study drug was correlated with ICU days, obesity was correlated with body mass index,
admission from home was correlated with admission from other).
a
“Admission, home” used admission, rehabilitation; or admission, nursing facility; or admission,
long-term care facility; or admission, transfer; or admission, homeless as a reference.

“Race, others” used White, African American, Latino, or Asian as a reference.

b

less afﬁnity to OAT-3 than piperacillin (log10P = + 0.737) and,
therefore, be less nephrotoxic when used with VAN as we demonstrated in our clinical analysis [42]. Interestingly, receipt of vasopressors, possibly a surrogate measure of compromised
oxygen delivery to the kidney and providing further mitochondrial stress, was also noted to be associated with AKI.

Our study is not without limitations. First, we did not include urine output, which is the gold standard, in our clinical
outcomes analysis. Urine output is associated with more frequent diagnosis of AKI but is challenging to assess in real-world
studies because it is not routinely and/or accurately collected
for all patients within the electronic medical records. In fact,
most clinical studies assessing AKI with VAN combinations
have not been able to include this variable [43]. Similarly, we
did not used the Kidney Disease Improving Global Outcomes
(KDIGO) deﬁnition in our study as it was not the standard
when enrollment was initiated. However, our selection of
RIFLE, AKIN, and VIN allowed us to successfully compare
our results with other VAN-TZP studies in the literature and
afﬁrm our ﬁndings. More research should be conducted to examine the results if the KDIGO deﬁnition were applied in protocols. Because it is not possible in the absence of a clinical trial
protocol to identify a patient’s true baseline SCr prior to admission, the baseline SCr deﬁnition used in our study may have
been more elevated than the true baseline, and this may have
underscored the extent of kidney injury. Nevertheless, this is
a common limitation with all real-world observational studies.
Additionally, we did not include other efﬁcacy-related clinical
outcomes in our cohort. This was, in part, due to the inherent
microbiological and selection differences between patients who
would receive TZP or C/T. Third, although the number of patients who received VAN-TZP in our cohort is signiﬁcantly
higher than for VAN- C/T, this mirrors the typical consumption of TZP vs C/T in the real-world setting, which increases
the external validity of our study. In addition, it met the

Figure 2. Kaplan–Meier analysis of time to nephrotoxicity for VAN-TZP and VAN-C/T. Survival estimate (ie, nonnephrotoxicity) was illustrated until the outcome of interest
(ie, nephrotoxicity) occurred or until they were censored. Time to acute kidney injury was measured from the combination start time until 72 hours after combination discontinuation. Abbreviations: CI, conﬁdence interval; VAN-C/T, vancomycin in combination with ceftolozane-tazobactam; VAN-TZP, vancomycin in combination with
piperacillin-tazobactam.
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prespeciﬁed power analysis and matching ratio. While we have
accounted for the impact of common nephrotoxins on the incidence of AKI, it is possible that factors such as nephrotoxin
dosing, duration, and other patient-related factors may have
emphasized the staging of AKI. These factors, nevertheless,
are less likely to impact the primary analysis because the primary end point was conservative and conclusive of all degrees of
AKI. In addition, our secondary subgroup analysis of patients
who are not on any nephrotoxins was consistent with the primary analysis as illustrated in the Supplementary Material.
In summary, we determined that the risk of AKI with
VAN-TZP administration is at least 3-fold higher compared
with VAN-C/T, which is consistent with evidence evaluating
VAN-TZP compared to other VAN-BL combinations
(VAN-FEP and VAN-MEM) [10–13, 17, 21]. Intrinsic hydrophobicity differences and therefore OAT-3 afﬁnity, proximal
tubular cell uptake, and accumulation may be the basis of these
observed differences. Future research should be directed toward determining the impact of VAN monitoring method
(ie, AUC vs trough) and other nephroprotective strategies on
the incidence of AKI when various VAN combinations are
used, particularly with TZP.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online.
Consisting of data provided by the authors to beneﬁt the reader, the posted
materials are not copyedited and are the sole responsibility of the authors,
so questions or comments should be addressed to the corresponding
author.
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